Once-yearly infusions of rituximab are as effective as twice-yearly dosing for sustained control of MS in a new phase 3 trial ...

A recent study finds that despite biosimilar use rising to 60% to 86% for three cancer drugs, predicted savings don’t match ...

For neuromyelitis optica spectrum disorder, long-term follow-up with a second-generation complement inhibitor shows an unprecedented level of disease control at 3 years.

The day Troy – a dedicated husband, high school track coach and technology professional – found an unusual lump on his back was the beginning of a life-altering journey with cancer. “I was at the ...

PR Newswire FORT LAUDERDALE, Fla., Sept. 25, 2025 With more than $45 million raised - including $4 million last year, 36,000 Totes for Hope delivered, 30 Breast Cancer Research Foundation grants ...

Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:58 PM EDTCompany ParticipantsMatthew Gline - ...

Although relapse rates were similar across all treatment categories, patients with GPA treated with rituximab monotherapy had a lower relapse risk relative to those on rituximab + cyclophosphamide ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Merck & Co., Inc. is placed fourth among them. Merck & Co., Inc. (NYSE:MRK), a global ...

Intel Corporation INTC recently secured a $5 billion investment from NVIDIA Corporation NVDA to jointly develop cutting-edge solutions that are likely to play an integral role in the evolution of the ...

The cancer medication Keytruda is the world’s bestselling drug. But with lower-priced competition set to arrive as soon as 2028, Keytruda’s manufacturer, Merck, is on the brink of losing tens of ...

Gautam Adani-led Adani Enterprises (AEL) will build a ropeway between Sonprayag and Kedarnath in Uttarakhand. The Adani Group’s flagship company has received a Letter of Award (LoA) from the National ...